News
On Wednesday, May 21, BMO Capital Markets reaffirmed its “Outperform” rating on Tourmaline Bio, Inc. (NASDAQ:TRML) with a price target of $35. The firm believes that the market’s negative ...
Tourmaline Bio (TRML) stock falls as the company posts mid-stage initial trial for lead asset pacibekitug in kidney disease patients with high CRP. Read more here.
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50.
On Wednesday, May 21, BMO Capital Markets reaffirmed its “Outperform” rating on Tourmaline Bio, Inc. (NASDAQ:TRML) with a price target of $35. The firm believes that the market’s negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback